Cantor Fitzgerald Reiterates Overweight on X4 Pharmaceuticals, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on X4 Pharmaceuticals (NASDAQ:XFOR) and maintained a $5 price target.
May 31, 2024 | 2:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on X4 Pharmaceuticals and maintained a $5 price target, indicating continued confidence in the company's stock performance.
The reiteration of an Overweight rating and maintenance of a $5 price target by a reputable analyst suggests positive sentiment and confidence in X4 Pharmaceuticals' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100